CAS 1234569-09-5

Lalistat 2

Description:

As of my last knowledge update in October 2023, "Lalistat 2" with the CAS number "1234569-09-5" does not appear to be a widely recognized or documented chemical substance in scientific literature or databases. It is possible that it is a proprietary compound, a research chemical, or a substance that has not been extensively characterized in public resources. Typically, the characteristics of a chemical substance would include its molecular formula, structure, physical properties (such as melting point, boiling point, solubility), and potential applications or biological activity. If "Lalistat 2" is related to a specific field, such as pharmaceuticals or materials science, further context may be necessary to provide more detailed information. For accurate and specific details, consulting specialized databases or scientific publications would be essential.

Formula: C₁₃H₂₀N₄O₂S

Synonyms:

• Lalistat 2 >=98% (HPLC)
• 4-(Piperidin-1-yl)-1,2,5-thiadiazol-3-yl piperidine-1-carboxylate
• lysosomal acid lipase deficiency,dried blood spot,Lalistat2,Lalistat-2,Inhibitor,cholesteryl ester storage disease,Lalistat 2,inhibit
• Lalistat 2

4-(Piperidin-1-yl)-1,2,5-thiadiazol-3-ylpiperidine-1-carboxylate

CAS: 1234569-09-5

Formula: C₁₃H₂₀N₄O₂S

Purity: 95%

Molecular weight: 296.3885

Ref: IN-DA01ENJ5

Lalistat 2

CAS: 1234569-09-5

Lalistat 2

Purity: ≥98%

Molecular weight: 296.39g/mol

Ref: 54-BUP09374

Lalistat 2

CAS: 1234569-09-5

Lalistat 2: selective lysosomal acid lipase inhibitor, IC50 152 nM, no effect on pancreatic/milk lipase <10 μM.

Formula: C₁₃H₂₀N₄O₂S

Purity: 99.84%

Color and Shape: Solid

Molecular weight: 296.39

Ref: TM-T41160

Lalistat 2

CAS: 1234569-09-5

Lalistat 2 is a drug that inhibits the activity of lipoprotein lipase and insulin resistance, which are both associated with metabolic disorders. Lalistat 2 has been shown to be effective against liver diseases such as fatty liver syndrome (hepatic steatosis) in animal studies. The drug also has anti-cancer effects, inhibiting the growth of cancer cells by inducing autophagy. This drug is not approved for use in pediatric patients because it is not known whether this drug will work safely in children. Lalistat 2 was developed using linear regression and logistic regression analyses on patient data from clinical trials.

Formula: C₁₃H₂₀N₄O₂S

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 296.39 g/mol

Ref: 3D-JZB56909